These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31050384)

  • 21. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
    Tang H; Dai Q; Shi W; Zhai S; Song Y; Han J
    Diabetologia; 2017 Oct; 60(10):1862-1872. PubMed ID: 28725912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
    Azharuddin M; Adil M; Ghosh P; Sharma M
    Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
    Li X; Li T; Cheng Y; Lu Y; Xue M; Xu L; Liu X; Yu X; Sun B; Chen L
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3170. PubMed ID: 30983141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials.
    Miyashita S; Kuno T; Takagi H; Sugiyama T; Ando T; Valentin N; Shimada YJ; Kodaira M; Numasawa Y; Kanei Y; Bangalore S
    Diabetes Res Clin Pract; 2020 May; 163():108136. PubMed ID: 32272190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.
    Rådholm K; Wu JH; Wong MG; Foote C; Fulcher G; Mahaffey KW; Perkovic V; Neal B
    Diabetes Res Clin Pract; 2018 Jun; 140():118-128. PubMed ID: 29604389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of sodium-glucose transporter 2 inhibitors on stroke in patients with type 2 diabetes: A meta-analysis.
    Pasqualotto E; Rodrigues FR; E Silva Ribeiro GB; de Oliveira Almeida G; Kabariti JC; Ferreira ROM; Chavez MP; Clemente MRC; Sur NB; Di Luca DG
    J Stroke Cerebrovasc Dis; 2024 Aug; 33(8):107730. PubMed ID: 38679214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of SGLT2 Inhibitors on Risk of Stroke in Diabetes: A Meta-Analysis.
    Zhang C; Zhang X; Wang P; Zhu Q; Mei Y; Zhang Z; Xu H
    Cerebrovasc Dis; 2022; 51(5):585-593. PubMed ID: 35100586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials.
    Spiazzi BF; Naibo RA; Wayerbacher LF; Piccoli GF; Farenzena LP; Londero TM; da Natividade GR; Zoldan M; Degobi NAH; Niches M; Lopes G; Boyko EJ; Utzschneider KM; Colpani V; Gerchman F
    Diabetes Res Clin Pract; 2023 Apr; 198():110621. PubMed ID: 36921905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials.
    Rong X; Li X; Gou Q; Liu K; Chen X
    Diab Vasc Dis Res; 2020; 17(5):1479164120953625. PubMed ID: 32981346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
    Zou CY; Liu XK; Sang YQ; Wang B; Liang J
    Medicine (Baltimore); 2019 Dec; 98(49):e18245. PubMed ID: 31804352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
    Robertson L; Yeoh SE; Stansby G; Agarwal R
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and risk factors for venous thromboembolism following surgical treatment of fractures below the hip: a meta-analysis.
    Tan L; Qi B; Yu T; Wang C
    Int Wound J; 2016 Dec; 13(6):1359-1371. PubMed ID: 26936798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are High- or Low-dose SGLT2 Inhibitors Associated With Cardiovascular and Respiratory Adverse Events? A Meta-analysis.
    Zou HT; Yang GH; Cai YJ; Chen H; Zheng XQ; Hu R
    J Cardiovasc Pharmacol; 2022 May; 79(5):655-662. PubMed ID: 35058411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Stroke and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Fatima K; Suri A; Rija A; Kalim S; Javaid S; Arif Z; Abedin MFE; Raza Y; Kalim N; Azam F; Musani S
    Curr Probl Cardiol; 2023 Apr; 48(4):101582. PubMed ID: 36584726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
    Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
    Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Zhang X; Zhong Z; Li Y; Li W
    Diabetes Metab Res Rev; 2020 Jul; 36(5):e3303. PubMed ID: 32134558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
    Wang Y; Wang M; Ni Y; Liang Z
    Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
    [No Abstract]   [Full Text] [Related]  

  • 40. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis.
    Ben-Aharon I; Stemmer SM; Leibovici L; Shpilberg O; Sulkes A; Gafter-Gvili A
    Acta Oncol; 2014 Sep; 53(9):1230-7. PubMed ID: 25162954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.